In vivo effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems

Thomas Paraidathathu, Alan B. Combs, James P. Kehrer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Doxorubicin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are anti-cancer drugs which have been used together in combination therapy of certain cancers. Each drug has been reported to affect intracellular glutathione stores and together, doxorubicin and BCNU have been shown to exert synergistic toxicity and to deplete completely the glutathione content of isolated hepatocytes. Cardiac and hepatic glutathione reductase activity was significantly inhibited following treatment in vivo with BCNU. Treatment of mice with both doxorubicin and BCNU resulted in increased mortality compared to either drug alone. There was, however, no depletion of hepatic or cardiac glutathione levels in vivo beyond that seen with either BCNU or doxorubicin alone. Diethyl maleate, a known glutathione depletor whose effects are enhanced by BCNU in vitro, also was unable to increase GSH depletion after BCNU in vivo. These discrepancies between in vivo and in vitro studies may be due to the presence of more effective compensatory mechanisms in the whole animal, or to differences in the metabolism and inactivation of these drugs.

Original languageEnglish
Pages (from-to)113-124
Number of pages12
JournalToxicology
Volume35
Issue number2
DOIs
Publication statusPublished - 1985
Externally publishedYes

Fingerprint

Carmustine
Doxorubicin
Glutathione
Liver
diethyl maleate
Pharmaceutical Preparations
Glutathione Reductase
Metabolism
Toxicity
Hepatocytes
Neoplasms
Animals
Mortality

Keywords

  • 1,3-Bis(2-chloroethyl)-1-nitrosourea
  • Adriamycin
  • Cardiac
  • Carmustine
  • Doxorubicin
  • Heart
  • Hepatic
  • Liver
  • Toxicology

ASJC Scopus subject areas

  • Toxicology

Cite this

In vivo effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems. / Paraidathathu, Thomas; Combs, Alan B.; Kehrer, James P.

In: Toxicology, Vol. 35, No. 2, 1985, p. 113-124.

Research output: Contribution to journalArticle

Paraidathathu, Thomas ; Combs, Alan B. ; Kehrer, James P. / In vivo effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems. In: Toxicology. 1985 ; Vol. 35, No. 2. pp. 113-124.
@article{0edc95197c744a9682fa21adb96f0e6e,
title = "In vivo effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems",
abstract = "Doxorubicin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are anti-cancer drugs which have been used together in combination therapy of certain cancers. Each drug has been reported to affect intracellular glutathione stores and together, doxorubicin and BCNU have been shown to exert synergistic toxicity and to deplete completely the glutathione content of isolated hepatocytes. Cardiac and hepatic glutathione reductase activity was significantly inhibited following treatment in vivo with BCNU. Treatment of mice with both doxorubicin and BCNU resulted in increased mortality compared to either drug alone. There was, however, no depletion of hepatic or cardiac glutathione levels in vivo beyond that seen with either BCNU or doxorubicin alone. Diethyl maleate, a known glutathione depletor whose effects are enhanced by BCNU in vitro, also was unable to increase GSH depletion after BCNU in vivo. These discrepancies between in vivo and in vitro studies may be due to the presence of more effective compensatory mechanisms in the whole animal, or to differences in the metabolism and inactivation of these drugs.",
keywords = "1,3-Bis(2-chloroethyl)-1-nitrosourea, Adriamycin, Cardiac, Carmustine, Doxorubicin, Heart, Hepatic, Liver, Toxicology",
author = "Thomas Paraidathathu and Combs, {Alan B.} and Kehrer, {James P.}",
year = "1985",
doi = "10.1016/0300-483X(85)90026-5",
language = "English",
volume = "35",
pages = "113--124",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - In vivo effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and doxorubicin on the cardiac and hepatic glutathione systems

AU - Paraidathathu, Thomas

AU - Combs, Alan B.

AU - Kehrer, James P.

PY - 1985

Y1 - 1985

N2 - Doxorubicin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are anti-cancer drugs which have been used together in combination therapy of certain cancers. Each drug has been reported to affect intracellular glutathione stores and together, doxorubicin and BCNU have been shown to exert synergistic toxicity and to deplete completely the glutathione content of isolated hepatocytes. Cardiac and hepatic glutathione reductase activity was significantly inhibited following treatment in vivo with BCNU. Treatment of mice with both doxorubicin and BCNU resulted in increased mortality compared to either drug alone. There was, however, no depletion of hepatic or cardiac glutathione levels in vivo beyond that seen with either BCNU or doxorubicin alone. Diethyl maleate, a known glutathione depletor whose effects are enhanced by BCNU in vitro, also was unable to increase GSH depletion after BCNU in vivo. These discrepancies between in vivo and in vitro studies may be due to the presence of more effective compensatory mechanisms in the whole animal, or to differences in the metabolism and inactivation of these drugs.

AB - Doxorubicin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) are anti-cancer drugs which have been used together in combination therapy of certain cancers. Each drug has been reported to affect intracellular glutathione stores and together, doxorubicin and BCNU have been shown to exert synergistic toxicity and to deplete completely the glutathione content of isolated hepatocytes. Cardiac and hepatic glutathione reductase activity was significantly inhibited following treatment in vivo with BCNU. Treatment of mice with both doxorubicin and BCNU resulted in increased mortality compared to either drug alone. There was, however, no depletion of hepatic or cardiac glutathione levels in vivo beyond that seen with either BCNU or doxorubicin alone. Diethyl maleate, a known glutathione depletor whose effects are enhanced by BCNU in vitro, also was unable to increase GSH depletion after BCNU in vivo. These discrepancies between in vivo and in vitro studies may be due to the presence of more effective compensatory mechanisms in the whole animal, or to differences in the metabolism and inactivation of these drugs.

KW - 1,3-Bis(2-chloroethyl)-1-nitrosourea

KW - Adriamycin

KW - Cardiac

KW - Carmustine

KW - Doxorubicin

KW - Heart

KW - Hepatic

KW - Liver

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=0021850254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021850254&partnerID=8YFLogxK

U2 - 10.1016/0300-483X(85)90026-5

DO - 10.1016/0300-483X(85)90026-5

M3 - Article

VL - 35

SP - 113

EP - 124

JO - Toxicology

JF - Toxicology

SN - 0300-483X

IS - 2

ER -